within Pharmacolibrary.Drugs.ATC.N;

model N05BA15
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 1.3333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0009,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 1200
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05BA15</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Camazepam is a benzodiazepine derivative primarily used for its anxiolytic, anticonvulsant, sedative, and muscle relaxant effects. It was previously used as an anxiolytic in some countries but is not widely approved or used in modern clinical practice.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult healthy volunteers, oral administration. No direct human clinical PK studies found in indexed literature.</p><h4>References</h4><ol><li><p>Morino, A, &amp; Sugiyama, M (1985). Relation between time courses of pharmacological effects and of plasma levels of camazepam and its active metabolites in rats. <i>Journal of pharmacobio-dynamics</i> 8(8) 597–606. DOI:<a href=&quot;https://doi.org/10.1248/bpb1978.8.597&quot;>10.1248/bpb1978.8.597</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2868088/&quot;>https://pubmed.ncbi.nlm.nih.gov/2868088</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05BA15;
